By Nexora Cyprus editorial team · General information — seek advice for your circumstances
Quick Summary
Cyprus tax residency and benefits require genuine management and control from Cyprus: real board meetings, Cyprus-resident directors making actual decisions, qualified local staff, and a real office. Nominee-only structures without genuine substance risk tax residency challenges and increased regulatory scrutiny.
A Cyprus company is a Cyprus tax resident — and therefore subject to Cyprus tax law, including all its benefits — only if it is 'managed and controlled' from Cyprus. This is the foundational test under Article 2 of the Cyprus Income Tax Law.
Without genuine management and control from Cyprus, the company may be treated as a tax resident of another country (wherever the effective management actually takes place), potentially triggering: tax liability in that other country on all profits; denial of double tax treaty benefits between Cyprus and third countries; disqualification from IP Box, participation exemption, and other Cyprus-specific tax reliefs; and regulatory scrutiny under CFC (Controlled Foreign Company) rules in the shareholders' home country.
Beyond the tax question, inadequate substance has become a direct compliance risk. Cyprus regulators and banks conduct substance reviews, and enforcement actions have increased significantly since 2022.
Management and control is determined by substance over form. A company is managed and controlled from the location where the real strategic decisions are made — not necessarily where the company is registered or where its paperwork says it operates.
The Cyprus Tax Department, following OECD guidelines, assesses management and control based on the following factors.
Management and Control — Key Factors
| Factor | Strong Substance | Weak Substance | Risk Level |
|---|---|---|---|
| Board composition | Majority of directors are Cyprus-resident individuals who actively participate in decisions | Majority of directors are non-resident; nominee directors with no real involvement | High |
| Board meetings | Held regularly in Cyprus; agenda and minutes reflect genuine deliberation | Rubber-stamp meetings; board meetings held abroad or by email only | High |
| Decision-making | Strategic and operational decisions made in Cyprus | Decisions made by shareholders abroad; directors just sign | High |
| Physical office | Real, functional office in Cyprus (not just a registered address) | Only a registered address / PO box / virtual office | Medium-High |
| Local staff | Qualified employees in Cyprus relevant to the business | No Cyprus-based staff; all work done abroad | Medium |
| Banking | Cyprus bank accounts operated from Cyprus | Bank accounts in other jurisdictions; no Cyprus banking | Medium |
| Records | Accounting records maintained and accessible in Cyprus | No Cyprus-based records; records held abroad | Medium |
For companies benefiting from specific regimes — notably the IP Box — the OECD modified nexus approach and Cyprus's implementation require that the Core Income-Generating Activities (CIGAs) are performed in Cyprus. CIGAs are the substantive activities that justify the income: for an IP holding company, this means actual R&D, development, and enhancement activities performed by qualified personnel in Cyprus, not just ownership of IP.
A Cyprus company that owns intellectual property but performs no actual R&D in Cyprus and employs no qualified tech staff locally will have a nexus fraction close to zero — eliminating the IP Box benefit in practice, regardless of the legal structure.
The consequences of inadequate substance have escalated significantly.
From a tax perspective: the company may be treated as a tax resident of another jurisdiction (where effective management is actually located), triggering full tax exposure in that jurisdiction; double tax treaty benefits may be denied under the anti-abuse provisions (Principal Purpose Test) of the OECD Multilateral Instrument; and specific regime benefits (IP Box, participation exemption) may be disallowed.
From a regulatory and banking perspective: Cyprus banks have substantially increased substance due diligence since 2021; accounts are refused or closed where substance is assessed as inadequate; the Cyprus AML framework imposes significant penalties on obliged entities (banks, accountants, lawyers) that maintain relationships with shell structures.
A substance review should document who makes decisions, where activities take place, and how the company’s resources support its income. Assess tax residence, permanent-establishment exposure, transfer pricing and AML duties separately; a registered address alone does not resolve those questions.
Evidence for a substance review
Keep evidence of the actual decision-makers, business activities, people and resources supporting the company. Review tax residence, transfer pricing and banking due diligence against those facts; a registered address alone is insufficient.
Cyprus Registrar company lifecycle and Cyprus Registrar forms and guidance publish the controlling material for this topic. Check the current law, form, circular or portal instructions before acting; this article is general information and the live official material prevails.
Related Guides
Disclaimer: This article is for informational purposes only and does not constitute legal, tax, or financial advice. Tax laws change frequently. Consult a qualified Cyprus adviser for guidance specific to your situation. The information on this page is general guidance only and does not constitute legal, tax, accounting, immigration or financial advice. Specific advice should be obtained based on the facts of each case.
— References linked in this article
Read each reference alongside the claim it accompanies and check current amendments before relying on it. General information — seek advice for your circumstances.
Related Articles
Our experts are ready to answer your questions.
Initial discussion · No obligation